You are here: Industry Insights > Tresiba

News List

Novo Nordisk's Tresiba misses main mark in head-to-head tilt with Sanofi's Toujeo fiercepharma
September 26, 2019
Novo also pointed to Tresiba’s ability to reduce the rate of severe hypoglycemia by 80% against Toujeo and pare down the rate of nocturnal hypoglycemia by 37% during that same 36-week period.
Novo cleared to add key data to Tresiba label pharmaphorum
March 29, 2018
Novo Nordisk can add data showing Tresiba can reduce the risk of hypoglycaemia to its label, a development which should help its fight competition from cheaper alternatives.
Insulia Receives FDA Clearance, CE Mark to Integrate Basaglar, Tresiba americanpharmaceuticacreview
November 17, 2017
Voluntis announced that Insulia, its digital companion for people with Type 2 diabetes, has received FDA clearance and the CE mark to integrate Basaglar and Tresiba.
Novo Nordisk CEO: Don't scapegoat pricing pressure. Better drugs grow anyway fiercepharma
August 10, 2017
Novo Nordisk CEO Lars Fruergaard Jorgensen said the company's portfolio will help it grow amid pricing challenges.
Switching to Tresiba pharmaasia
June 21, 2017
Switching to Tresiba provides significant reductions in blood glucose and lower rates of hypoglycaemia in a real-world setting.